Literature DB >> 26407783

Time to abandon placebo control in pivotal phase III trials?

John R Geddes1, Andrea Cipriani1.   

Abstract

Year:  2015        PMID： 26407783      PMCID： PMC4592650          DOI： 10.1002/wps.20246

Source DB:  PubMed          Journal:  World Psychiatry        ISSN： 1723-8617            Impact factor:   49.548


× No keyword cloud information.
  9 in total

1.  The scientific and ethical basis for placebo-controlled trials in depression and schizophrenia: an FDA perspective.

Authors:  T P Laughren
Journal:  Eur Psychiatry       Date:  2001-11       Impact factor: 5.361

2.  Placebo in clinical trials for depression: complexity and necessity.

Authors:  David J Kupfer; Ellen Frank
Journal:  JAMA       Date:  2002-04-10       Impact factor: 56.272

3.  What comparative effectiveness research is needed? A framework for using guidelines and systematic reviews to identify evidence gaps and research priorities.

Authors:  Tianjing Li; S Swaroop Vedula; Roberta Scherer; Kay Dickersin
Journal:  Ann Intern Med       Date:  2012-03-06       Impact factor: 25.391

4.  Leveraging crowdsourcing to facilitate the discovery of new medicines.

Authors:  Thea C Norman; Chas Bountra; Aled M Edwards; Keith R Yamamoto; Stephen H Friend
Journal:  Sci Transl Med       Date:  2011-06-22       Impact factor: 17.956

5.  The impact of restrictive entry criterion during the placebo lead-in period.

Authors:  R Landin; D J DeBrota; T A DeVries; W Z Potter; M A Demitrack
Journal:  Biometrics       Date:  2000-03       Impact factor: 2.571

6.  The nature of placebo response in clinical studies of major depressive disorder.

Authors:  George I Papakostas; Søren D Østergaard; Nadia Iovieno
Journal:  J Clin Psychiatry       Date:  2015-04       Impact factor: 4.384

Review 7.  Placebo response in studies of major depression: variable, substantial, and growing.

Authors:  B Timothy Walsh; Stuart N Seidman; Robyn Sysko; Madelyn Gould
Journal:  JAMA       Date:  2002-04-10       Impact factor: 56.272

Review 8.  Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis.

Authors:  Andrea Cipriani; Toshiaki A Furukawa; Georgia Salanti; John R Geddes; Julian Pt Higgins; Rachel Churchill; Norio Watanabe; Atsuo Nakagawa; Ichiro M Omori; Hugh McGuire; Michele Tansella; Corrado Barbui
Journal:  Lancet       Date:  2009-02-28       Impact factor: 79.321

9.  Antidepressants versus placebo in major depression: an overview.

Authors:  Arif Khan; Walter A Brown
Journal:  World Psychiatry       Date:  2015-10       Impact factor: 49.548
  9 in total
  2 in total

Review 1.  Valproate for acute mania.

Authors:  Janina Jochim; Raphael P Rifkin-Zybutz; John Geddes; Andrea Cipriani
Journal:  Cochrane Database Syst Rev       Date:  2019-10-07

2.  Impact of placebo arms on outcomes in antidepressant trials: systematic review and meta-regression analysis.

Authors:  Georgia Salanti; Anna Chaimani; Toshi A Furukawa; Julian P T Higgins; Yusuke Ogawa; Andrea Cipriani; Matthias Egger
Journal:  Int J Epidemiol       Date:  2018-10-01       Impact factor: 7.196
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.